SOLUTION / PUBLIC SOURCE RECORD
SERO: pioneering trust in medical laboratory diagnostics
- Published 22 August 2024; updated 23 March 2026; estimated reading time 3 minutes. Listed under Health and life science / Medtech and available in the Americas, Europe, Asia, Africa and Oceania.
- SERO supplies independent third-party quality-control materials for medical laboratory instruments. The page says its purpose is to help laboratories produce reliable, comparable test results over time and between laboratories. It describes the company as independent of instrument manufacturers, aligning with the cited ISO quality and competence standard for medical laboratories.
- The article traces the company’s history to control sera developed at Oslo University Hospital in the 1950s and says SERO was established 13 years later, in 1963, launching Seronorm®, described as the first commercially available control serum. Seronorm® Immunoassay Control contains more than 50 analytes in one bottle, according to the CEO.
- Most SERO products are said to contain over 95% human serum without stabilisers or preservatives to better resemble patient samples (“commutable” controls). The page argues that patient-like controls can reveal instrument malfunctions that affect real samples, while some other controls may not behave like patient material. SERO also aims to make universal controls compatible across analytical platforms.
- The article says SERO exports 90% of production, has international partners on every continent and is one of five competitive companies in its market. It cites a global in-vitro-diagnostics quality-control market forecast of USD 2.28 billion by 2031, growing 4.5% annually from 2024 to 2031; this is a forecast rather than a reported outcome.
- Linked to SDG 3 (Good health and well-being).
- Contact: Stefan Kernstock, CEO, s.kernstock@sero.no. Company: SERO AS, Stasjonsveien 44, 1396 Billingstad, Norway; sero.no. No phone-number reveal control was shown in the captured page.